SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-010072 to KAMADA LTD (KMDA) (CIK 0001567529) (KMDA)

KAMADA LTD (KMDA) (CIK 0001567529)
Date: Sept. 12, 2023 · CIK: 0001567529 · Accession: 0000000000-23-010072

AI Filing Summary & Sentiment

File numbers found in text: 333-274443

Date
September 12, 2023
Author
Not clearly detected
Form
UPLOAD
Company
KAMADA LTD (KMDA) (CIK 0001567529)

Letter

United States securities and exchange commission logo September 12, 2023 Amir London Chief Executive Officer Kamada Ltd. 2 Holzman Street Science Park, P.O. Box 4081 Rehovot 7670402 Re:Kamada Ltd. Registration Statement on Form F-3 Filed September 11, 2023 File No. 333-274443 Dear Amir London: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jackie Liu

Show Raw Text
United States securities and exchange commission logo
September 12, 2023
Amir London
Chief Executive Officer
Kamada Ltd.
2 Holzman Street
Science Park, P.O. Box 4081
Rehovot 7670402
Re:Kamada Ltd.
Registration Statement on Form F-3
Filed September 11, 2023
File No. 333-274443
Dear Amir London:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Jackie Liu